MRVI as reported
Maravai LifeSciences Holdings, Inc. reported $205M of revenue over the trailing twelve months, −15% on the year before. 11 reported series are charted on this page, each one as filed.
$205M
Revenue, trailing twelve months · to Q1 2026 · −15% against the twelve months before
- Net Income
- −$105M
Net Income · −36% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$53M
Free Cash Flow · +140% year on year · trailing twelve months to Q1 2026
- Op Margin
- −90%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $205M | −15% | Q1 2026 |
| Net Income | −$105M | −36% | Q1 2026 |
| EPS | −$0.71 | −38% | Q1 2026 |
| Gross Margin | 27% | n/a | Q1 2026 |
| Op Margin | −90% | n/a | Q1 2026 |
| Net Margin | −56% | n/a | Q1 2026 |
| ROE | −58% | n/a | Q1 2026 |
| ROA | −17% | n/a | Q1 2026 |
| ROIC | −61% | n/a | Q1 2026 |
| Free Cash Flow | −$53M | +140% | Q1 2026 |
| P/E | 22.9 | n/a | Q3 2023 · 10 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Maravai LifeSciences Holdings, Inc. (MRVI) - Revenue & ProfitRevenue & ProfitMaravai LifeSciences Holdings, Inc. (MRVI)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com